ERBB2 and cancer: Preclinical studies on β--TRT have been performed in several cancer models, including multiple myeloma 144, breast and ovarian cancer 95,145, and non-Hodgkin lymphoma 96, using nanobodies targeting the 5T2MM paraprotein, HER2 and CD20, respectively.